U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07059091) titled 'Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD' on July 01.
Brief Summary: This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies.
Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease (COPD)
Allergies
Intervention:
DRUG: Omalizumab (Xolair(R))
...